View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
May 30, 2018

Treeway reports positive results in Phase I study of TW001 for ALS

Treeway has reported positive results from a Phase I clinical trial designed to analyse the bioavailability of TW001 in comparison with Radicavaâ for the treatment of amyotrophic lateral sclerosis (ALS).

Treeway has reported positive results from a Phase I clinical trial designed to analyse the bioavailability of TW001 in comparison with Radicavaâ for the treatment of amyotrophic lateral sclerosis (ALS).

Findings of the trial have showed increased bioavailability of TW001 in a single-dose treatment, with no safety concerns developed within the subject group.

Theresults have implied the potential of TW001 to improve treatment strategies for ALS patients.

During the randomised cross-over comparative bioavailability trial, a single oral dose of 140mg of TW001 was tested against a one-hour intravenous infusion of 60mg of Radicavaâin 18 healthy subjects.

Treeway chief development officer Ronald van der Geest said: “It is Treeway’s mission to identify novel treatment routes for ALS patients and we believe that this study indicates that an oral formulation of edavarone may offer patients a better quality-of-life through a simpler and more effective route of administration.

“We can initiate a pivotal Phase lll study and move rapidly toward bringing TW001 to patients.”

“Given the nature of this programme and based on the positive results we have seen in this comparative study, we can initiate a pivotal Phase lll study and move rapidly toward bringing TW001 to patients.”

TW001, an oral formulation of edaravone, has been developed as a disease-modifying drug for all phenotypes of ALS, and can be used daily to improve patient convenience.

ALS is also called Lou Gehrig’s Disease, which is a progressive neurodegenerative rare condition that causes muscle weakness, disability and eventually death.

The disease, which most frequently attacks people between the ages of 40 and 60, is estimated to affect nearly two people per 100,000 annually.

There is currently no treatment available for ALS.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU